Search Bar & Filters
Found 15 Actively Recruiting clinical trials
Actively Recruiting
This research aims to evaluate the effectiveness, safety, and tolerability of combining baxdrostat with dapagliflozin compared to dapagliflozin alone in people with chronic kidney disease CKD and high blood pressure. The goal is to reduce the risk of serious kidney problems, heart failure events, or cardiovascular death. This is a phase III, international, multicenter, randomized, double-blind, placebo-controlled, event-driven study focused on treatment outcomes. Participants who do not already use SGLT2 inhibitors will first undergo a 4-week dapagliflozin run-in period. After that, they will be randomly assigned to receive either baxdrostat plus dapagliflozin or placebo plus dapagliflozin. Baxdrostat dosing may start low and be increased if needed. Study visits will occur frequently early on at 2, 4, 8, 16, 34, and 52 weeks post-randomization, then approximately every 4 months. The study will end when a predetermined number of kidney or cardiovascular events occur. During the study, participants will have scheduled visits for assessments including kidney function, heart health, and safety monitoring. If they stop the study treatment early, they will continue on dapagliflozin alone and remain in the trial for follow-up visits. Researchers will measure outcomes such as sustained kidney function decline, kidney failure, heart failure events, cardiovascular death, and all-cause death over up to 37 months. Data collection continues until the study closes, with safety and tolerability closely observed throughout.
Actively Recruiting
Researchers are evaluating the efficacy and safety of eloralintide compared with placebo in adults with persistent obesity or overweight. Participants may have type 2 diabetes or not, and all are on stable background therapy with a weekly incretin. This phase 3 randomized, double-blind study aims to understand the effects of eloralintide on body weight and related health outcomes. Participants will be randomly assigned to receive one of four doses of eloralintide or a placebo, all given by subcutaneous injection once weekly. The study treatment period lasts for 64 weeks, during which participants receive their assigned injections. This is a parallel group study, meaning each participant receives only one assigned treatment throughout the trial. Participant involvement spans about 80 weeks, including screening, treatment, and follow-up. Researchers will monitor changes in body weight, waist circumference, blood pressure, blood sugar, insulin, kidney function, inflammation markers, and quality of life using questionnaires. Safety and medication use will also be tracked. Visits and assessments will occur regularly to evaluate the treatment effects and participant well-being.
Actively Recruiting
Researchers are studying the effects of orforglipron compared to a placebo in adults aged 50 and older who have atherosclerotic cardiovascular disease ASCVD andor chronic kidney disease CKD. This Phase 3 trial aims to evaluate how orforglipron impacts major cardiovascular events over about five years of participation. Participants will be randomly assigned to receive either orforglipron orally along with standard care or a placebo orally with standard care. The study is double-blind, meaning neither participants nor researchers know who receives the active drug or placebo. This design helps measure the drugs impact on cardiovascular health and kidney function over the study duration. During the study, participants will be monitored regularly to track the time to the first major cardiovascular event and other health outcomes such as kidney function changes and the onset of type 2 diabetes. The study involves ongoing assessments from baseline through the five-year period, including follow-ups to ensure safety and gather detailed health information.
Actively Recruiting
Researchers are evaluating the safety, tolerability, pharmacokinetics, and effectiveness of surovatamig in adults with primary membranous nephropathy pMN, a kidney disease marked by the presence of anti-PLA2R antibodies and heavy proteinuria. This Phase II open-label study focuses on participants at high risk of progressing to end-stage kidney disease. The study is conducted at 30 to 40 sites across about 10 countries and sponsored by AstraZeneca. Participants will receive surovatamig by subcutaneous injection over two parts Part A with multiple ascending doses and sentinel dosing, and Part B with multiple ascending doses. Each part includes three periods screening, treatment, and follow-up, with the entire study lasting up to 26 months. The study tracks participants during treatment and after to assess ongoing effects. During participation, individuals will undergo regular assessments including urine protein measurements, antibody levels, blood cell counts, and evaluations of symptoms related to pMN. Safety is closely monitored through reports of adverse events over an average of 2 years. Researchers will also study how the body processes surovatamig and its impact on disease remission and relapse. The total participation may last up to 26 months with extensive follow-up to observe outcomes.
Actively Recruiting
Researchers are evaluating the effects of felzartamab in adults with Immunoglobulin A nephropathy IgAN, a kidney disease caused by the buildup of abnormal IgA antibodies in the kidneys. This buildup leads to inflammation and damage, resulting in protein in the urine proteinuria. The study aims to learn how felzartamab affects proteinuria and kidney function compared to a placebo, while also assessing the safety and how the drug is processed by the body. Participants will be randomly assigned to receive either intravenous IV infusions of felzartamab or a placebo that contains no active medicine. The treatment period lasts for 24 weeks, followed by an 80-week follow-up period. Some participants with lower kidney filtration rates will be included in specific cohorts receiving either felzartamab or placebo. Overall, participants will have 17 study visits during about 2 years in the trial. During the study, participants will undergo various assessments including urine protein measurement, kidney function tests using estimated glomerular filtration rate eGFR, and monitoring for immune responses and adverse events. Blood samples will be collected to measure drug levels and antibodies against felzartamab. Safety will be monitored through vital signs, laboratory tests, physical exams, and ECGs. Researchers will evaluate changes from baseline up to 36 weeks for proteinuria and up to 104 weeks for kidney function and safety outcomes.
Actively Recruiting
Researchers are evaluating the effects of muvalaplin in reducing the risk of major cardiovascular events in adults with elevated lipoproteina levels who either have cardiovascular disease or are at risk for a heart attack or stroke. This Phase 3, randomized, double-blind, placebo-controlled study focuses on adults with high lipoproteina and a history or risk of atherosclerotic cardiovascular events. The study aims to better understand if muvalaplin can lower the occurrence of serious heart-related problems. Participants will be randomly assigned to receive either muvalaplin or a placebo, both taken orally. The study compares these two groups over about 5.25 years to assess the impact of muvalaplin on major adverse cardiac events. The research includes ongoing monitoring of lipoproteina levels and other cardiovascular outcomes throughout this period. During the study, participants will undergo regular assessments including measuring changes in lipoproteina, tracking the time to occurrence of major cardiovascular events, and monitoring overall health outcomes. Researchers will collect data on healthcare resource usage and drug levels in the body. The long-term follow-up allows for thorough evaluation of muvalaplins effects on heart health and safety over more than five years.
Actively Recruiting
Researchers are conducting a prospective, multicenter registry to observe the real-world use of coronary function tests in routine Belgian medical practice. These tests may include bolus thermodilution measurements of coronary microvascular function and invasive vasoreactivity tests using acetylcholine. The study aims to understand how often these tests are performed, the reasons for testing, and the frequencies of coronary microvascular dysfunction and coronary artery vasospasm. Participants scheduled for coronary function tests will have data collected from their medical records regarding cardiovascular risk factors, past medical history, non-invasive test results, procedural details, and follow-up visits. There are no study-specific visits planned. Optionally, participants may complete questionnaires about their anginal symptoms and quality of life. No interventions are administered as part of this observational study. Participants involvement includes routine data collection from medical files over a follow-up period of up to five years. Researchers will measure the frequency of coronary microvascular dysfunction and coronary artery vasospasm, as well as describe predictors for these conditions and major adverse cardiovascular events over one and three years among different patient groups. The study is organized by the University Hospital, Antwerp, and aims to provide valuable insights into coronary function testing practices and outcomes.
Actively Recruiting
Researchers are conducting a combined phase 2b and phase 3 clinical trial to study CSL300 Clazakizumab in adults with end stage kidney disease ESKD who are undergoing maintenance dialysis. The study aims to find the right dose of CSL300 and then evaluate its effects on cardiovascular outcomes and safety in people with systemic inflammation and either atherosclerotic cardiovascular disease ASCVD or diabetes. This multicenter, randomized, double-blind, placebo-controlled trial is designed to provide detailed information on the drugs impact and risks. The study is divided into two parts. Part 1 phase 2b focuses on identifying the optimal dose of CSL300 compared to a placebo over 12 weeks. Part 2 phase 3 assesses the efficacy and safety of CSL300 versus placebo on cardiovascular events such as cardiovascular death or heart attack over approximately 5 years. Participants receive intravenous doses of CSL300 or placebo. The placebo matches the CSL300 product minus the active ingredient. Participants will be monitored through regular assessments including blood tests to measure markers of inflammation like high-sensitivity C-reactive protein hs-CRP, other blood components, and drug levels. The trial tracks cardiovascular events and safety outcomes over the study period. The research team will also observe changes in several blood markers related to inflammation and cardiovascular health. The total follow-up may last up to about five years to fully capture long-term effects and safety.
Actively Recruiting
Researchers are evaluating whether the antiarrhythmic drug flecainide is as safe as standard rhythm-control drugs sotalol or amiodarone in adults aged 18 years and older who have atrial fibrillation AF with stable coronary artery disease CAD. The study aims to determine if flecainide leads to similar or fewer serious side effects, hospitalizations, or deaths compared to standard treatments. This Phase 4 randomized trial compares these treatments in patients with documented AF and stable CAD. Participants are randomly assigned to receive either flecainide or standard rhythm-control medication sotalol or amiodarone as part of their routine clinical care. Flecainide dosing starts at 100 to 150 mg per day, taken in divided doses or once daily with controlled release, combined with an AV nodal blocker. Sotalol dosing starts at 80 mg twice daily, with adjustments for kidney function, while amiodarone treatment involves a loading phase followed by maintenance dosing. Treatment follows physician preference and patient needs. During the study, participants attend regular hospital visits and telephone follow-ups. They undergo routine heart tests including electrocardiograms and echocardiography, and complete questionnaires about symptoms, quality of life, and daily functioning. Researchers monitor safety outcomes, heart rhythm, healthcare use, and quality of life for at least one year. The main outcome measured is a composite safety outcome after one year of treatment.
Actively Recruiting
Researchers are comparing outcomes and complications between two types of medial unicompartmental knee prostheses used in knee surgery fixed bearing FB and mobile bearing MB designs. The study focuses on adults aged 50 to 80 with medial gonarthrosis. The FB design is simpler to implant but may wear out earlier, while the MB design may improve joint movement and load distribution but carries risks of insert dislocation and fractures. MB implants can also be cementless, potentially reducing surgery time and cement-related issues. Participants will receive either a mobile or fixed unicompartmental knee prosthesis. The study will measure various clinical and radiological outcomes, including surgery time, complications, and revision rates within two years after surgery. The study will assess outcomes such as the Oxford Knee Score OKS, Arthrogenic Muscle Inhibition AMI, pain scales, and quality of life questionnaires at several time points up to 24 months postoperatively. Participants will be evaluated before surgery and at multiple follow-up visits at 6 weeks, 4 months, 12 months, and 24 months after surgery. Assessments include clinical exams, imaging for bone and joint condition, and questionnaires on pain and function. The study tracks complications, any need for revision surgery, and muscle inhibition to understand the differences in performance and safety between the two prosthesis types over two years.
1-10 of 15
1